Prostamax

Prostamax is a peptide bioregulator derived from prostate gland tissue, developed as part of the Khavinson organ-specific bioregulator programme. Following the established methodology of extracting organ-specific regulatory peptides, Prostamax contains the short peptide sequences isolated from prostatic tissue that demonstrate tissue-specific gene regulatory activity in prostate cells.

The prostate gland is particularly susceptible to age-related dysfunction. Benign prostatic hyperplasia (BPH) - the non-malignant enlargement of the prostate that affects the majority of men over 50 - is driven by a combination of altered androgen sensitivity, increased prostatic cell proliferation, and chronic low-grade inflammation. Additionally, the risk of prostate cancer increases dramatically with age, and the distinction between benign and malignant prostatic changes is an active area of research.

Prostamax is researched in the context of supporting normal prostate cell function and counteracting age-related prostatic deterioration. The proposed mechanisms involve regulation of gene expression in prostate epithelial and stromal cells, modulation of inflammatory signalling within the prostatic microenvironment, and normalisation of growth factor signalling that drives hyperplastic changes.

Russian clinical research into Prostamax has focused primarily on its potential to improve urinary flow parameters in men with age-related prostate dysfunction - a functional outcome directly relevant to quality of life. Improved uroflowmetry alongside reduced inflammatory markers suggests that Prostamax may address both the obstructive and inflammatory components of prostatic aging.

In comprehensive bioregulator protocols for male aging, Prostamax is often combined with Testagen (which targets the pituitary-gonadal axis) to address both the reproductive endocrine system and the target organ simultaneously. This dual approach - hormonal axis support plus tissue-specific bioregulation - reflects the comprehensive nature of the Khavinson longevity protocol design.